By: Benzinga
UPDATE: Bank of America Raises PO to $42 on Aegerion Pharmaceuticals; Juxtapid Launch Solid
Bank of America maintained Aegerion Pharmaceuticals (NASDAQ: AEGR ) with a Buy rating and raised the price objective from $39.00 to $42.00. Bank of America noted, "On its 4Q12 call, AEGR provided a launch update for Juxtapid in HoFH treatment, which began in the US in mid-January. While 85
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here